Harpoon Therapeutics (NASDAQ:HARP) PT Lowered to $40.00 at Canaccord Genuity Group
Harpoon Therapeutics (NASDAQ:HARP – Free Report) had its price target cut by Canaccord Genuity Group from $80.00 to $40.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $45.00 price objective on shares of Harpoon […]
United States Delphia United States Inc Harpoon Therapeutics Inc Canaccord Genuity Group Sequoia Financial Advisors Harpoon Therapeutics Company Profile
Source: tickerreport.com